Newcastle disease virus (NDV or AOaV-1) is an avian paramyxovirus that typically causes only mild, self-limiting disease in humans. Here, we report fatal neuroinvasive AOaV-1 infection in a patient with multiple myeloma receiving maintenance therapy with teclistamab, daratumumab, and lenalidomide following frontline te...
Christina Krueger, C. Schaefers, T. Guenther et al.· Acta Neuropathologica· 0 citations
The BELI(E)VE trial aims to establish a novel personalized therapeutic approach for a specific subset of MM patients by combining belantamab mafodotin and venetoclax, potentially inducing deep and durable remissions in t(11;14)-positive RRMM patients.
C. Schaefers, Cyrus Khandanpour, M. Hänel et al.· BMC Cancer· 0 citations
(GPRC5D) is a leading immunotherapy target in multiple myeloma (MM), with diverse GPRC5D-targeting agents — including T-cell engagers (TCE), antibody – drug conjugates
Ricardo Ahrens, K. Ahrens, Maximilian Al-Bazaz et al.· Blood Cancer Journal· 0 citations
Deeper pre-infusion response was associated with significantly lower toxicity after BCMA-directed CAR-T therapy, identifying pre-infusion disease control as a potentially modifiable determinant of toxicity.
J. Artzenroth, R. Kosch, Maximilian Al-Bazaz et al.· Transplantation and Cellular...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.